PharmaResearch Co., Ltd. (KOSDAQ:214450)
South Korea flag South Korea · Delayed Price · Currency is KRW
289,000
+500 (0.17%)
Jun 12, 2026, 3:30 PM KST

PharmaResearch Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
565,479536,289350,115261,011194,759154,083
Other Revenue
----0-0-0
565,479536,289350,115261,011194,759154,083
Revenue Growth (YoY)
44.14%53.17%34.14%34.02%26.40%41.69%
Cost of Revenue
126,783125,07298,87870,75353,24645,750
Gross Profit
438,696411,217251,237190,258141,513108,333
Selling, General & Admin
161,992149,77294,67073,82858,57242,832
Research & Development
38,14335,85821,17615,0308,7026,738
Amortization of Goodwill & Intangibles
4,3344,2943,7453,5213,7963,592
Other Operating Expenses
995.98702.31618.58556.23648.65313.55
Operating Expenses
213,531198,891125,18798,00175,59755,844
Operating Income
225,166212,327126,05192,25865,91652,489
Interest Expense
-10,288-10,392-4,634-2,987-3,830-1,314
Interest & Investment Income
17,61616,23210,1747,4035,2723,726
Earnings From Equity Investments
-5,411-2,927----
Currency Exchange Gain (Loss)
4,273-907.854,955-379.95207.69155.77
Other Non Operating Income (Expenses)
-1,752-1,343-6,0283,396-3,220124.32
EBT Excluding Unusual Items
229,605212,989130,51799,69064,34655,181
Gain (Loss) on Sale of Investments
10,1155,081-14,2384,210-5,0231,462
Gain (Loss) on Sale of Assets
-189.45-162.14-11.9236.11-113.69229.6
Asset Writedown
-1,202-1,394--3,231-5,161-839.66
Other Unusual Items
261.74--454.59---
Pretax Income
238,591216,514115,813100,70554,04856,033
Income Tax Expense
57,61448,25926,87023,44010,6149,210
Earnings From Continuing Operations
180,977168,25588,94377,26543,43446,824
Minority Interest in Earnings
-4,456-3,1343,100-713.44-2,857-134.98
Net Income
176,522165,12192,04376,55140,57746,689
Net Income to Common
176,522165,12192,04376,55140,57746,689
Net Income Growth
59.07%79.40%20.24%88.66%-13.09%42.45%
Shares Outstanding (Basic)
101010101010
Shares Outstanding (Diluted)
121210111010
Shares Change (YoY)
11.63%12.34%-2.50%5.85%-0.76%5.74%
EPS (Basic)
16989.7715892.838940.877571.244067.474716.62
EPS (Diluted)
15849.2914932.758940.877487.074067.004714.88
EPS Growth
49.31%67.02%19.42%84.09%-13.74%36.78%
Free Cash Flow
149,907153,435101,70752,88342,14744,652
Free Cash Flow Per Share
12905.4613266.869879.605008.314224.854441.83
Dividend Per Share
3700.0003700.0001100.000950.000660.000600.000
Dividend Growth
236.36%236.36%15.79%43.94%10.00%20.00%
Gross Margin
77.58%76.68%71.76%72.89%72.66%70.31%
Operating Margin
39.82%39.59%36.00%35.35%33.84%34.06%
Profit Margin
31.22%30.79%26.29%29.33%20.83%30.30%
Free Cash Flow Margin
26.51%28.61%29.05%20.26%21.64%28.98%
EBITDA
241,400228,142139,696104,25376,51862,041
EBITDA Margin
42.69%42.54%39.90%39.94%39.29%40.27%
D&A For EBITDA
16,23515,81513,64511,99610,6029,552
EBIT
225,166212,327126,05192,25865,91652,489
EBIT Margin
39.82%39.59%36.00%35.35%33.84%34.06%
Effective Tax Rate
24.15%22.29%23.20%23.28%19.64%16.44%
Advertising Expenses
-53,34629,64222,60118,3819,339